These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29052238)

  • 1. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.
    Kawamoto K; Miyoshi H; Suzuki T; Sasaki Y; Yamada K; Yanagida E; Muto R; Kiryu M; Sone H; Seto M; Ohshima K; Takizawa J
    Hematol Oncol; 2018 Feb; 36(1):166-173. PubMed ID: 29052238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
    Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
    Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities.
    Kim WY; Nam SJ; Kim S; Kim TM; Heo DS; Kim CW; Jeon YK
    Leuk Lymphoma; 2015 Jun; 56(6):1778-86. PubMed ID: 25288491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of mature T-cell and NK-cell lymphoma with CD30 expression based on latest WHO classification].
    Feng Y; Fu J; Yan S; Ling Y; Huang Y; Cai M; Rao H
    Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):508-11. PubMed ID: 25346118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type.
    Li P; Jiang L; Zhang X; Liu J; Wang H
    BMC Cancer; 2014 Nov; 14():890. PubMed ID: 25429803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma.
    Shen Z; Wang Y; Xie R; Zhang Q; Xing X; Zhang S; Liu H; Sang W
    Am J Clin Pathol; 2024 Jul; 162(1):95-102. PubMed ID: 38387041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type.
    Hong J; Park S; Baek HL; Jung JH; Kang IG; Sym SJ; Park J; Ahn JY; Cho EK; Kim ST; Shin DB; Lee JH
    Int J Clin Exp Pathol; 2012; 5(9):939-47. PubMed ID: 23119111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological study of pulmonary extranodal nature killer/T-cell lymphoma, nasal type and literature review.
    Ding W; Wang J; Zhao S; Yang Q; Sun H; Yan J; Gao L; Yao W; Zhang W; Liu W
    Pathol Res Pract; 2015 Jul; 211(7):544-9. PubMed ID: 25953340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study.
    Pongpruttipan T; Sukpanichnant S; Assanasen T; Wannakrairot P; Boonsakan P; Kanoksil W; Kayasut K; Mitarnun W; Khuhapinant A; Bunworasate U; Puavilai T; Bedavanija A; Garcia-Herrera A; Campo E; Cook JR; Choi J; Swerdlow SH
    Am J Surg Pathol; 2012 Apr; 36(4):481-99. PubMed ID: 22314189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
    Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
    Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
    Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R
    Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD30-positive cutaneous extranodal natural killer/T-cell lymphoma: clinicopathological features and survival outcomes.
    Lee WJ; Moon IJ; Shin HJ; Won CH; Chang SE; Choi JH; Lee MW
    Int J Dermatol; 2019 Jun; 58(6):688-696. PubMed ID: 30597548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both c-Myc and Ki-67 expression are predictive markers in patients with extranodal NK/T-cell lymphoma, nasal type: a retrospective study in China.
    Huang X; Sun Q; Fu H; Zhou X; Guan X; Wang J
    Pathol Res Pract; 2014 Jun; 210(6):351-6. PubMed ID: 24642368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas.
    Malysz J; Erdman P; Klapper J; Zhu J; Creer M; Bayerl MG
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):429-33. PubMed ID: 27521276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
    Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
    Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Flow-Cytometry-Based Immunophenotyping Analysis for Accurate Diagnosis and Management of Extranodal NK/T Cell Lymphoma, Nasal Type.
    Wang JC; Deng XQ; Liu WP; Gao LM; Zhang WY; Yan JQ; Ye YX; Liu F; Zhao S
    Cytometry B Clin Cytom; 2020 Jan; 98(1):28-35. PubMed ID: 31313887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
    Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.